

Product Data Sheet

Product Name: INX-315

Cat. No.: GC73965

Chemical Properties

Cas. No. 2745060-92-6


Formula $C_{19}H_{21}N_7O_3S$ M.Wt 427.48

Solubility DMSO : 100 mg/mL (233.93 mM; Storage -20°C
Need ultrasonic)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

dependent manner in xenograft mouse models. INX-315 may be used in cancer research.

INX-315 (30-300 nM, 24 hours) inhibits cell cycle progression in OVCAR3 and MKN1 cells by reducing retinoblastoma protein (Rb) phosphorylation[1]. INX-315 (0.3 nM to 10 μ M, 6 days) inhibits cell proliferation in CCNE1-amplified ovarian carcinoma cell line[1].

INX-315 (100 mg/kg, p.o., twice daily for 56 days) effectively inhibits tumor growth in a gastric adenocarcinoma BALB/c nude mouse model[1]. INX-315 (100 mg/kg twice daily or 200 mg/kg once daily, i.p.) demonstrates significant tumor inhibition in the OVCAR3 ovarian cancer CDX model with good tolerance[2]. INX-315 (100 mg/kg twice daily, i.p.) demonstrates significant antitumor activity in the GA0103 gastric cancer PDX model with good tolerance[2].

References:

- [1]. Dietrich C, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. *Cancer Discov.* 2023 Dec 4.
- [2]. Trub A G, et al. INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers[J]. *Cancer Research*, 2023, 83(7_Supplement): 5994-5994.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA